Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma - Jiang, H; Lwin, T; Zhao, X (Br J Haematol, 2019)
et al.